PARK8 (LRRK2) Antibody (Y2475) Blocking Peptide
€363.00
In stock
SKU
AC-BP7099k
Background:
Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.
Other Names:
Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin, LRRK2, PARK8
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7099k was selected from the LRRK2 region of human PARK8 (LRRK2). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: LRRK2
Gene ID: 120892
Primary Accession: Q5S007
Other Accession: NP_940980
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.
Other Names:
Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin, LRRK2, PARK8
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7099k was selected from the LRRK2 region of human PARK8 (LRRK2). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: LRRK2
Gene ID: 120892
Primary Accession: Q5S007
Other Accession: NP_940980
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review